Kristie L. Kahl

A blood test may help to identify the best treatment option for patients with ALK-positive, advanced non-small cell lung cancer, sparing patients from having to undergo an invasive biopsy.

Dr. Patrick I. Borgen discussed estrogen receptor-positive breast cancer and why it is important for patient to understand what this means for their treatment.

A recent study found no different in disease recurrence among men with prostate cancer when they were given radiation after surgery or not.

Phase 3 trial findings showed that treatment with Lynparza delayed disease progression by about four months compared with newer hormonal agents in pre-treated patients with metastatic castration-resistant prostate cancer and faulty DNA repair genes.

In this episode of the "CURE Talks Cancer" podcast, the keynote speaker for the CURE Patient-Focused Sessions at the New York Lung Cancers Symposium shares how a pain under her arm led to her diagnosis in less than 48 hours.

“Survivors living with recurrent breast cancer have unique needs and programs that address these needs can enhance patient satisfaction,” the study authors wrote.

CURE spoke with an expert on how patients can better advocate for themselves when it comes to genetic testing and its follow-up.

Two studies showed that adding a CDK4/6 inhibitor to treatment with Faslodex improved survival among women with hormone receptor-positive, human epidermal growth factor2-negative advanced breast cancer.

First-line Tagrisso significantly extended overall survival compared with first generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer, according to results from the phase 3 FLAURA study.

One in two patients with metastatic melanoma is alive five years following treatment with Opdivo plus Yervoy, according to long-term follow-up of the phase 3 CheckMate 067 trial.

Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.

First-line treatment with Opdivo plus low-dose Yervoy improved survival among patients with advanced NSCLC compared to chemotherapy, according to results from the CheckMate-227 trial.

The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.

The Food and Drug Administration expanded its approval of Cologuard, an at-home non-invasive colorectal cancer screening test, to include use among average-risk individuals aged 45 and older.

Here is a list of the recent trial initiations that occurred within the cancer space in September.

A recent survey found that lung cancer stigma can be a barrier to treatment; however, on the plus side, the percentage of people who associate the disease with smoking has dropped in recent years.

CURE spoke with an expert from Mount Sinai to discuss the future of ovarian cancer treatment and his advice for women facing a new diagnosis.

A subgroup of women with advanced endometrial cancer now have a second-line treatment option to turn to after progressing on chemotherapy.

Men with castration-sensitive prostate cancer now have an option for when treatment with androgen deprivation therapy alone is not enough.

Dana Vaughns and his colleagues rode 3,000 miles across the U.S. in support of funding research for the V Foundation.

A recent survey showed that most Americans do not know what cutaneous squamous cell carcinoma is and how severe the disease can be if it advances.

Researchers at Roswell Park Comprehensive Cancer Center found a biomarker that may help to determine which patients with hepatocellular carcinoma will respond to treatment with Nexavar, leading to more individualized treatment options.

Twist Out Cancer has paired those touched by cancer with an artist, who creates a unique piece of artwork that reflects on their individual journey with cancer.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with a skin cancer survivor who has dealt with many recurrences over the last 30 years and tells others to “listen to your mother” and protect your skin from the sun.

One expert discusses the current treatment options for patients with mantle cell lymphoma as well as the potential shift away from chemotherapy in the future.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Brilliantly founder Kristen Carbone about her family risk for cancer and why she started her site to broaden the scope of breast cancer navigation.

The Food and Drug Administration issued guidelines to hopefully broaden clinical trial criteria for breast cancer studies to include men.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Matt Newman, who was diagnosed with brain cancer at 39, but refuses to let cancer define the legacy he has made.

CURE spoke with Ryan Anthony, a Dallas Symphony trumpet player, about how his passion for music led to his myeloma diagnosis and the start of his foundation CancerBlows.